The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Gonadotrophin-releasing hormone antagonists for assisted reproductive technology
Open accessAbstract
BACKGROUND: Gonadotrophin-releasing hormone (GnRH) antagonists can be used to prevent a luteinizing hormone (LH) surge during controlled ovarian hyperstimulation (COH) without the hypo-oestrogenic side-effects, flare-up, or long down-regulation period associated with agonists. The antagonists directly and rapidly inhibit gonadotrophin release within several hours through competitive binding to pituitary GnRH receptors. This property allows their use at any time during the follicular phase. Several different regimens have been described including multiple-dose fixed (0.25 mg daily from day six to seven of stimulation), multiple-dose flexible (0.25 mg daily when leading follicle is 14 to 15 mm), and single-dose (single administration of 3 mg on day 7 to 8 of stimulation) protocols, with or without the addition of an oral contraceptive pill. Further, women receiving antagonists have been shown to have a lower incidence of ovarian hyperstimulation syndrome (OHSS). Assuming comparable clinical outcomes for the antagonist and agonist protocols, these benefits would justify a change from the standard long agonist protocol to antagonist regimens. This is an update of a Cochrane review first published in 2001, and previously updated in 2006 and 2011. OBJECTIVES: To evaluate the effectiveness and safety of gonadotrophin-releasing hormone (GnRH) antagonists compared with the standard long protocol of GnRH agonists for controlled ovarian hyperstimulation in assisted conception cycles. SEARCH METHODS: We searched the Cochrane Menstrual Disorders and Subfertility Group Trials Register (searched from inception to May 2015), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, inception to 28 April 2015), Ovid MEDLINE (1966 to 28 April 2015), EMBASE (1980 to 28 April 2015), PsycINFO (1806 to 28 April 2015), CINAHL (to 28 April 2015) and trial registers to 28 April 2015, and handsearched bibliographies of relevant publications and reviews, and abstracts of major scientific meetings, for example the European Society of Human Reproduction and Embryology (ESHRE) and American Society for Reproductive Medicine (ASRM). We contacted the authors of eligible studies for missing or unpublished data. The evidence is current to 28 April 2015. SELECTION CRITERIA: Two review authors independently screened the relevant citations for randomised controlled trials (RCTs) comparing different GnRH agonist versus GnRH antagonist protocols in women undergoing in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI). DATA COLLECTION AND ANALYSIS: Two review authors independently assessed trial eligibility and risk of bias, and extracted the data. The primary review outcomes were live birth and ovarian hyperstimulation syndrome (OHSS). Other adverse effects (miscarriage and cycle cancellation) were secondary outcomes. We combined data to calculate pooled odds ratios (ORs) and 95% confidence intervals (CIs). Statistical heterogeneity was assessed using the I(2) statistic. We assessed the overall quality of the evidence for each comparison using GRADE methods. MAIN RESULTS: We included 73 RCTs, with 12,212 participants, comparing GnRH antagonist to long-course GnRH agonist protocols. The quality of the evidence was moderate: limitations were poor reporting of study methods.Live birthThere was no conclusive evidence of a difference in live birth rate between GnRH antagonist and long course GnRH agonist (OR 1.02, 95% CI 0.85 to 1.23; 12 RCTs, n = 2303, I(2)= 27%, moderate quality evidence). The evidence suggested that if the chance of live birth following GnRH agonist is assumed to be 29%, the chance following GnRH antagonist would be between 25% and 33%.OHSSGnRH antagonist was associated with lower incidence of any grade of OHSS than GnRH agonist (OR 0.61, 95% C 0.51 to 0.72; 36 RCTs, n = 7944, I(2) = 31%, moderate quality evidence). The evidence suggested that if the risk of OHSS following GnRH agonist is assumed to be 11%, the risk following GnRH antagonist would be between 6% and 9%.Other adverse effectsThere was no evidence of a difference in miscarriage rate per woman randomised between GnRH antagonist group and GnRH agonist group (OR 1.04, 95% CI 0.82 to 1.30; 33 RCTs, n = 7022, I(2) = 0%, moderate quality evidence).With respect to cycle cancellation, GnRH antagonist was associated with a lower incidence of cycle cancellation due to high risk of OHSS (OR 0.47, 95% CI 0.32 to 0.69; 19 RCTs, n = 4256, I(2) = 0%). However cycle cancellation due to poor ovarian response was higher in women who received GnRH antagonist than those who were treated with GnRH agonist (OR 1.32, 95% CI 1.06 to 1.65; 25 RCTs, n = 5230, I(2) = 68%; moderate quality evidence). AUTHORS' CONCLUSIONS: There is moderate quality evidence that the use of GnRH antagonist compared with long-course GnRH agonist protocols is associated with a substantial reduction in OHSS without reducing the likelihood of achieving live birth.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Daya, S., Maheshwari, A., Siristatidis, C. S., Bhattacharya, S., & Gibreel, A. (2000) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001299 · Cited by 149
RetractedPreferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Wang, G., Ma, R., Qiao, G., Wada, K., Aizawa, Y., & Satoh, T. (2015) · Integrative Medicine International · doi:10.1159/000368408 · Cited by 18,657
Hao (2015) · doi:10.1002/14651858 · Cited by 11,321
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2004) · Human Reproduction · doi:10.1093/humrep/deh098 · Cited by 6,138
CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials
Schulz, K. F., Altman, D. G., Moher, D., & for the CONSORT Group* (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-11-201006010-00232 · Cited by 3,824
(2008) · Cited by 3,790
Moher, D., Pham, B., Jones, A., Cook, D. J., Jadad, A. R., Moher, M., Tugwell, P., & Klassen, T. P. (1998) · The Lancet · doi:10.1016/s0140-6736(98)01085-x · Cited by 3,560
Chapter 9: Analysing Data and Undertaking Meta-Analyses
Deeks, J. J., Higgins, J. P. T., & Altman, D. G. (2008) · Cited by 2,782
CLINICAL ASSESSMENT OF BODY HAIR GROWTH IN WOMEN
FERRIMAN, D., & GALLWEY, J. D. (1961) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-21-11-1440 · Cited by 2,506
Ovarian Hyperstimulation Syndrome: An Update Review
GOLAN, A., RON-EL, R., HERMAN, A., & SOFFER, Y. (1989) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-198906000-00004 · Cited by 806
Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review
Delvigne, A. (2002) · Human Reproduction Update · doi:10.1093/humupd/8.6.559 · Cited by 717
Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment
Wallach, E. E., Navot, D., Bergh, P. A., & Laufer, N. (1992) · Fertility and Sterility · doi:10.1016/s0015-0282(16)55188-7 · Cited by 621
Baart, E. B., Martini, E., Eijkemans, M. J., Van Opstal, D., Beckers, N. G. M., Verhoeff, A., Macklon, N. S., & Fauser, B. C. J. M. (2007) · Human Reproduction · doi:10.1093/humrep/del484 · Cited by 609
Engmann, L., DiLuigi, A., Schmidt, D., Nulsen, J., Maier, D., & Benadiva, C. (2008) · Fertility and Sterility · doi:10.1016/j.fertnstert.2007.02.002 · Cited by 422
Hughes, E. G., Fedorkow, D. M., Daya, S., Sagle, M. A., Van de Koppel, P., & Collins, J. A. (1992) · Fertility and Sterility · doi:10.1016/s0015-0282(16)55430-2 · Cited by 402
The European Orgalutran® Study Group, Borm, G., & Mannaerts, B. (2000) · Human Reproduction · doi:10.1093/humrep/15.7.1490 · Cited by 376
A mild treatment strategy for in-vitro fertilisation: a randomised non-inferiority trial
Heijnen, E. M., Eijkemans, M. J., De Klerk, C., Polinder, S., Beckers, N. G., Klinkert, E. R., Broekmans, F. J., Passchier, J., Te Velde, E. R., Macklon, N. S., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60360-2 · Cited by 349
Self-citationBosch, E., Valencia, I., Escudero, E., Crespo, J., Simón, C., Remohí, J., & Pellicer, A. (2003) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.07.002 · Cited by 343
Albano, C., Felberbaum, R. E., Smitz, J., Riethmüller-Winzen, H., Engel, J., Diedrich, K., & Devroey, P. (2000) · Human Reproduction · doi:10.1093/humrep/15.3.526 · Cited by 312
Kolibianakis, E. M., Collins, J., Tarlatzis, B. C., Devroey, P., Diedrich, K., & Griesinger, G. (2006) · Human Reproduction Update · doi:10.1093/humupd/dml038 · Cited by 306
Hohmann, F. P., Macklon, N. S., & Fauser, B. C. J. M. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020788 · Cited by 281
Olivennes, F., Belaisch-Allart, J., Emperaire, J.-C., Dechaud, H., Alvarez, S., Moreau, L., Nicollet, B., Zorn, J.-R., Bouchard, P., & Frydman, R. (2000) · Fertility and Sterility · doi:10.1016/s0015-0282(99)00524-5 · Cited by 257
Gonadotrophin-releasing hormone antagonists for assisted conception
Al-Inany, H. G., Abou-Setta, A. M., & Aboulghar, M. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001750.pub2 · Cited by 247
Self-citationThe European Middle East Orgalutran® Study Group (2001) · Human Reproduction · doi:10.1093/humrep/16.4.644 · Cited by 241
Gonadotrophin-releasing hormone antagonists for assisted reproductive technology
Al-Inany, H. G., Youssef, M. A., Aboulghar, M., Broekmans, F. J., Sterrenburg, M. D., Smit, J. G., & Abou-Setta, A. M. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001750.pub3 · Cited by 199
Self-citationde Vantéry Arrighi, C., Lucas, H., Chardonnens, D., & de Agostini, A. (2009) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-7-1 · Cited by 188
THROMBOEMBOLIC PHENOMENA AFTER OVARIAN STIMULATION WITH HUMAN GONADOTROPHINS
Mozes, M., Bogokowsky, H., Antebi, E., Lunenfeld, B., Rabau, E., Serr, D. M., David, A., & Salomy, M. (1965) · The Lancet · doi:10.1016/s0140-6736(65)90636-7 · Cited by 182
Cheung, L.-P., Lam, P.-M., Lok, I. H., Chiu, T. T.-Y., Yeung, S.-Y., Tjer, C.-C., & Haines, C. J. (2005) · Human Reproduction · doi:10.1093/humrep/deh668 · Cited by 176
Lainas, T. G., Sfontouris, I. A., Zorzovilis, I. Z., Petsas, G. K., Lainas, G. T., Alexopoulou, E., & Kolibianakis, E. M. (2009) · Human Reproduction · doi:10.1093/humrep/dep436 · Cited by 171
The clinical therapeutic window for luteinizing hormone in controlled ovarian stimulation
Shoham, Z. (2002) · Fertility and Sterility · doi:10.1016/s0015-0282(02)03157-6 · Cited by 168
Olivennes, F. J., Alvarez, S., Bouchard, P., Fanchin, R. R. F., Salat‐Baroux, J., & Frydman, R. (1998) · Human Reproduction · doi:10.1093/humrep/13.9.2411 · Cited by 152
Are GnRH antagonists comparable to agonists for use in IVF?
Huirne, J. A. F., Homburg, R., & Lambalk, C. B. (2007) · Human Reproduction · doi:10.1093/humrep/dem270 · Cited by 152
Olivennes, F. J., Fanchin, R. R. F., Bouchard, P., de Ziegler, D., Taieb, J., Selva, J., & Frydman, R. (1994) · Fertility and Sterility · doi:10.1016/s0015-0282(16)56933-7 · Cited by 136
Duijkers, I. J., Klipping, C., Willemsen, W. N., Krone, D., Schneider, E., Niebch, G., & Hermann, R. (1998) · Human Reproduction · doi:10.1093/humrep/13.9.2392 · Cited by 114
Sunkara, S. K., Coomarasamy, A., Faris, R., Braude, P., & Khalaf, Y. (2013) · Fertility and Sterility · doi:10.1016/j.fertnstert.2013.09.035 · Cited by 111
Optimizing GnRH antagonist administration: meta-analysis of fixed versus flexible protocol
Al-Inany, H. G., Aboulghar, M. A., Mansour, R., & Serour, G. I. (2005) · Reproductive BioMedicine Online · doi:10.1016/s1472-6483(10)61661-6 · Cited by 111
Self-citationBarmat, L. I., Chantilis, S. J., Hurst, B. S., & Dickey, R. P. (2005) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.06.076 · Cited by 111
Griesinger, G., Venetis, C. A., Marx, T., Diedrich, K., Tarlatzis, B. C., & Kolibianakis, E. M. (2007) · Fertility and Sterility · doi:10.1016/j.fertnstert.2007.07.1354 · Cited by 97
Rombauts, L. J. F., Healy, D., & Norman, R. J. (2005) · Human Reproduction · doi:10.1093/humrep/dei302 · Cited by 91
D’Amato, G., Caroppo, E., Pasquadibisceglie, A., Carone, D., Vitti, A., & Vizziello, G. M. (2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.01.022 · Cited by 90
de Klerk, C., Macklon, N., Heijnen, E., Eijkemans, M. J. C., Fauser, B. C. J. M., Passchier, J., & Hunfeld, J. A. M. (2007) · Human Reproduction · doi:10.1093/humrep/dem171 · Cited by 89
Revelli, A., Chiadò, A., Dalmasso, P., Stabile, V., Evangelista, F., Basso, G., & Benedetto, C. (2014) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-014-0227-y · Cited by 86
Polinder, S., Heijnen, E., Macklon, N., Habbema, J. D. F., Fauser, B. C. J. M., & Eijkemans, M. J. C. (2007) · Human Reproduction · doi:10.1093/humrep/dem372 · Cited by 82
Review of the evidence base of strategies to prevent ovarian hyperstimulation syndrome
Mathur, R., Kailasam, C., & Jenkins, J. M. (2007) · Human Fertility · doi:10.1080/14647270601111239 · Cited by 81
Hwang, J. (2004) · Human Reproduction · doi:10.1093/humrep/deh375 · Cited by 78
Albano, C., Smitz, J. E. J., Camus, M., Riethmüller-Winzen, H., Siebert-Weigel, M., Diedrich, K., Steirteghem, A. C. V., & Devroey, P. (1996) · Human Reproduction · doi:10.1093/oxfordjournals.humrep.a019058 · Cited by 75
Gonadotrophin-releasing hormone antagonists for assisted conception
Al-Inany, H. G., & Aboulghar, M. A. (2001) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001750 · Cited by 69
Self-citationSerafini, P. C., Yadid, I. M., Motta, E. L. A., Alegretti, J. R., Fioravanti, J., & Coslovsky, M. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2006.02.110 · Cited by 67
Mohsen, I. A., & Din, R. E. E. (2012) · Gynecological Endocrinology · doi:10.3109/09513590.2012.730569 · Cited by 66
Crosignani, P. G., & Somigliana, E. (2006) · Human Reproduction · doi:10.1093/humrep/del416 · Cited by 61
GnRH agonist versus GnRH antagonist in oocyte donation cycles: a prospective randomized study
Prapas, N., Prapas, Y., Panagiotidis, Y., Prapa, S., Vanderzwalmen, P., Schoysman, R., & Makedos, G. A. (2005) · Human Reproduction · doi:10.1093/humrep/deh832 · Cited by 58
Kurzawa, R., Ciepiela, P., Bączkowski, T., Safranow, K., & Brelik, P. (2008) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-008-9249-7 · Cited by 53
Sauer, M. V., Thornton, M. H., Schoolcraft, W. B., & Frishman, G. N. (2004) · Reproductive BioMedicine Online · doi:10.1016/s1472-6483(10)61631-8 · Cited by 51
Comparison of mild stimulation and conventional stimulation in ART outcome
Karimzadeh, M., Ahmadi, S., Oskouian, H., & Rahmani, E. (2009) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-009-1252-4 · Cited by 50
Eijkemans, M. J. C., Heijnen, E., de Klerk, C., Habbema, J. D. F., & Fauser, B. C. J. M. (2005) · Human Reproduction · doi:10.1093/humrep/dei332 · Cited by 44
Xavier, P., Gamboa, C., Calejo, L., Silva, J., Stevenson, D., Nunes, A., & Martinez‐de‐Oliveira, J. (2005) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2004.11.005 · Cited by 43
Lainas, T. G., Petsas, G. K., Zorzovilis, I. Z., Iliadis, G., Lainas, G. T., Cazlaris, H. E., & Kolibianakis, E. M. (2007) · Human Reproduction · doi:10.1093/humrep/dem033 · Cited by 42
Lee, T., Wu, M., Chen, H., Chen, M., Ho, H., & Yang, Y. (2005) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.12.037 · Cited by 40
Comparison of mild and microdose GnRH agonist flare protocols on IVF outcome in poor responders
Karimzadeh, M., Mashayekhy, M., Mohammadian, F., & Moghaddam, F. M. (2011) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-010-1828-z · Cited by 36
Vlaisavljević, V., Reljič, M., Lovrec, V. G., & Kovačič, B. (2003) · Reproductive BioMedicine Online · doi:10.1016/s1472-6483(10)61868-8 · Cited by 35
Loutradis, D., Stefanidis, K., Drakakis, P., Milingos, S., Antsaklis, A. J., & Michalas, S. S. (2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.04.051 · Cited by 31
Kim, Y. J., Ku, S., Jee, B. C., Suh, C. S., Kim, S. H., Choi, Y. M., Kim, J. G., & Moon, S. Y. (2010) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-010-1401-9 · Cited by 28
Qiao, J., Lu, G., Zhang, H. W., Chen, H., Ma, C., Olofsson, J. I., Witjes, H., Heijnen, E., & Mannaerts, B. M. J. L. (2012) · Gynecological Endocrinology · doi:10.3109/09513590.2012.665103 · Cited by 25
Zikopoulos, K., Kaponis, A. I., Adonakis, G., Sotiriadis, A., Kalantaridou, S., Georgiou, I. A., & Paraskevaidis, E. A. (2005) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.11.060 · Cited by 24
Seminal bacterial pathogens and in vitro fertilization
Hewitt, J., Cohen, J., Fehilly, C. B., Rowland, G., Steptoe, P. C., Webster, J., Edwards, R., & Fishel, S. B. (1985) · Journal of Assisted Reproduction and Genetics · doi:10.1007/bf01139342 · Cited by 23
Khalaf, M., Mittre, H., Levallet, J., Hanoux, V., Denoual‐Ziad, C., Herlicoviez, M., Bonnamy, P., & Benhaïm, A. (2010) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2010.03.017 · Cited by 22
Ferrari, B., Pezzuto, A., Barusi, L., & Coppola, F. (2005) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2005.08.017 · Cited by 21
Seow, K., Lin, Y., Hsieh, B., Huang, L., Huang, S.-C., Chen, C.-Y., Chen, P.-H., Tzeng, C., & Hwang, J. (2010) · Gynecologic and Obstetric Investigation · doi:10.1159/000290062 · Cited by 18
Stenbæk, D. S., Toftager, M., Hjordt, L. V., Jensen, P. S., Holst, K. K., Bryndorf, T., Holland, T., Bogstad, J. W., Pinborg, A. B., HORNNES, P. J., et al. (2014) · Human Reproduction · doi:10.1093/humrep/deu294 · Cited by 18
Rinaldi, L., Lisi, F., & Selman, H. A. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-013-0021-1 · Cited by 16
Mohamed, K. A., Davies, W. A. R., & Lashen, H. (2006) · Gynecological Endocrinology · doi:10.1080/09513590500519260 · Cited by 11
Fıçıcıoğlu, C., Kumbak, B., Akçin, O., Attar, R., Yıldırım, G., & Yeşildağlar, N. (2010) · Gynecological Endocrinology · doi:10.3109/09513590903215557 · Cited by 11
Fıçıcıoğlu, C., Kumbak, B., Akçin, O., Attar, R., Yıldırım, G., & Yeşildağlar, N. (2009) · Gynecological Endocrinology · doi:10.1080/09513590903215557 · Cited by 9
Cited by
Epidemiology, diagnosis, and management of polycystic ovary syndrome
Sirmans, S., & Pate, K. (2013) · Clinical Epidemiology · doi:10.2147/clep.s37559 · Cited by 1,302
The physiology and clinical utility of anti-Müllerian hormone in women
Dewailly, D., Andersen, C. Y., Balen, A., Broekmans, F., Dilaver, N., Fanchin, R., Griesinger, G., Kelsey, T. W., La Marca, A., Lambalk, C., et al. (2014) · Human Reproduction Update · doi:10.1093/humupd/dmt062 · Cited by 1,049
Self-citationLa Marca, A., & Sunkara, S. K. (2014) · Human Reproduction Update · doi:10.1093/humupd/dmt037 · Cited by 586
ESHRE guideline: ovarian stimulation for IVF/ICSI†
The ESHRE Guideline Group on Ovarian Stimulation, Bosch, E., Broer, S., Griesinger, G., Grynberg, M., Humaidan, P., Kolibianakis, E., Kunicki, M., La Marca, A., Lainas, G., et al. (2020) · Human Reproduction Open · doi:10.1093/hropen/hoaa009 · Cited by 543
Self-citationAn OHSS-Free Clinic by segmentation of IVF treatment
Devroey, P., Polyzos, N. P., & Blockeel, C. (2011) · Human Reproduction · doi:10.1093/humrep/der251 · Cited by 514
Metadata
- Authors
- Al-Inany, H. G., Youssef, M. A., Ayeleke, R. O., Brown, J., Lam, W. S., & Broekmans, F. J.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2016-04-29
- Volume
- 2016
- Issue
- 8
- Pages
- CD001750-CD001750
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1600600005
- Cited by
- 600
- References
- 77
- FWCI
- 67.05
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.